- $67.08m
- $56.92m
- $62.66m
- 81
- 61
- 35
- 60
Annual income statement for Bioqual, fiscal year end - May 31st, USD millions except per share, conversion factor applied.
2019 May 31st | 2020 May 31st | 2021 May 31st | 2022 May 31st | 2023 May 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 39.5 | 46.4 | 57.7 | 66.2 | 62.7 |
| Cost of Revenue | |||||
| Gross Profit | 7.41 | 9.69 | 14 | 13 | 8.64 |
| Selling / General / Administrative Expenses | |||||
| Total Operating Expenses | 35.9 | 41 | 49.1 | 59.6 | 61.6 |
| Operating Profit | 3.58 | 5.32 | 8.56 | 6.53 | 1.1 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 3.71 | 5.49 | 8.62 | 6.58 | 1.13 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 2.75 | 4.23 | 6.33 | 5.26 | 0.836 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | 2.83 | 4.23 | 6.33 | 5.26 | 0.836 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 2.83 | 4.23 | 6.33 | 5.26 | 0.836 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 3.08 | 4.73 | 7.08 | 5.88 | 0.934 |
| Dividends per Share |